-Economic and Political Weekly The compulsory licence for Nexavar is only the beginning of a new battle over drug prices. The grant of a compulsory licence (CL) to Natco Pharma, a relatively small Indian pharmaceutical company, to manufacture and sell the cancer drug sorafenib (Nexavar) has been rightly hailed as a major step forward for public health and the wider availability of life saving medicines.   The German pharmaceutical company Bayer holds the patent...

The Centre on Monday revised the wage rate under the Mahatma Gandhi National Rural Employment Guarantee Act and has decided to amend the Act to remove the existing disparity in minimum wage, even as the matter is scheduled to come up before the Supreme Court on April 9. The revision in the wage rate indexed to the Consumer Price Index for Agricultural Labour (CPIAL) will come into effect on April 1...

-Economic and Political Weekly   Budget 2012, built yet again at the altar of fiscal fundamentalism, will not convince anybody. In this era of immediate assessment it took just a few minutes for the Union Budget for 2012-13 to be given one or the other negative appellation – “lacklustre”, “anti-growth”, “back to the 1980s”, “without reform” and the like. Such evaluations forget that union budgets have long since ceased to be statements of...

Inequality in India is worsening and clearly following the US pattern India is a “relatively low-income inequality country” – to borrow an expression from a World Bank publication – when compared to China or Brazil, but there is no doubt that disparities have been widening of late. Planning Commission officials have admitted that inequality has risen in the first decade of the new millennium, although the factors responsible for it need...

India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...